Incyte announces FDA approval of Zynyz(TM), indicated for the treatment of metastatic or recurrent locally advanced Merkel Cell Carcinoma (MCC)
Incyte announces FDA approval of Zynyz(TM), indicated for the treatment of metastatic or recurrent locally advanced Merkel Cell Carcinoma (MCC) (skincancer )The active substance is the monoclonalantibody Retifanlimab, expressed using recombinant Chinese Hamster Ovary (CHO). Once again, the role of CHO cells in the development of new therapies has been essential and their use in research and development to produce and select candidates is intensive. […]